Adaptimmune Therapeutics: Q2 Earnings Insights


Adaptimmune Therapeutics ADAP reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM.

Here's what investors need to know about the announcement.


Adaptimmune Therapeutics beat estimated earnings by 80.0%, reporting an EPS of $-0.05 versus an estimate of $-0.25.

Revenue was up $2.44 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.17 which was followed by a 1.3% increase in the share price the next day.

Here's a look at Adaptimmune Therapeutics's past performance:


Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -0.22 0.14 -0.26 -0.24
EPS Actual -0.05 -0.04 -0.30 -0.24
Revenue Estimate 3.29M 96.45M 1.37M 1.36M
Revenue Actual 3.58M 1.42M 1.20M 3.10M

To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings




Posted In: EarningsNewsBZI-Recaps